Beigene (688235.SH) releases its semi-annual report: Product revenue reaches 11.908 billion yuan, accelerating the construction of a research, production, sales, and innovation closed-loop.
On August 29, Beigene (688235.SH) released its 2024 interim report on the A-share market, leveraging its systematic advantages in global research and development, overseas registration, quality control, and market commercialization to continuously promote the international marketization of its core products, Baiyueze (Zebutinib) and Baize'an (Toripalimab).
Beigene Inc. (688235.SH) saw a sharp increase in revenue in the first half of the year, up 65.44% to 11.996 billion yuan, and achieved a significant reduction in losses. Sales of Baiyueze surged 122%.
Beigene (688235.SH) released its 2024 semi-annual report, with the company achieving revenue of 1...
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
BeiGene Reports Strong Revenue Growth and Reduced Losses
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
